Summary:
- C4 Therapeutics, a clinical-stage biopharmaceutical company, will present preliminary data from the Phase 1 clinical trial of its monotherapy drug CFT1946 at the European Society for Medical Oncology (ESMO) Congress 2024.
- CFT1946 is a novel targeted protein degrader that is being evaluated as a potential treatment for various types of cancer.
- The Phase 1 trial is designed to assess the safety, tolerability, and preliminary anti-tumor activity of CFT1946 in patients with advanced or metastatic solid tumors.